Tom 19, Nr 4 (2023)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2024-02-07
Wyświetlenia strony
332
Wyświetlenia/pobrania artykułu
50
Przegląd piśmiennictwa
1
DOI: 10.5603/ppn.98865
Pol. Przegl. Neurol 2023;19(4):336-339.
Streszczenie
Brak
Referencje
- Maj E, Wolak T, de Meulder J, et al. Differences in diffusion tensor imaging parameters of brain white matter tracts between patients with myotonic dystrophy type 1 and type 2 - a retrospective single-centre study. Neurol Neurochir Pol. 2023; 57(5): 430–437.
- Fang CE, Bokre D, Wong SH. Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: a systematic review and meta-analysis. Neurology. 2023; 101(16): e1594–e1605.
- Sassi S, Bianchi E, Diamanti L, et al. Retrospective observational study on the use of acetyl-L-carnitine in ALS. J Neurol. 2023; 270(11): 5344–5357.
- Bishara H, Arbel A, Barnett-Griness O, et al. Association between Guillain-Barré syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology. 2023; 101(20): e2035–e2042.
- Henzi BC, Schmidt S, Nagy S, et al. North Star Consortium. Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2023; 22(10): 890–899.
- Keddie S, Smyth D, Keh RYS, et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain. 2023; 146(11): 4562–4573.
- Dubbioso R, Provitera V, Pacella D, et al. Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study. J Neurol. 2023; 270(10): 4968–4977.
